SCHEMBL1617764

SCHEMBL1617764

CCOC(=O)c1cc(OCc2ccccc2)c(OC)cc1-c1noc(C)n1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.46
NPC1 O15118 2/20 0.45
HPGD P15428 1/20 0.45
RAB9A P51151 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
MEN1 O00255 1/20 0.45
HSP90AA1 P07900 1/20 0.45
KMT2A Q03164 1/20 0.45
SMPD1 P17405 2/20 0.44
MAOB P27338 1/20 0.43
SRD5A1 P18405 2/20 0.42
SRD5A2 P31213 2/20 0.42
PPIA P62937 1/20 0.42
HDAC1 Q13547 1/20 0.42
HDAC8 Q9BY41 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
F2 P00734 1/20 0.42
APP P05067 1/20 0.41
POLB P06746 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1617879 0.92 SMPD1 (0.47) NPC1HPGDRAB9ASMN1; SMN2MEN1
SCHEMBL8040270 0.92 SMPD1 (0.44) NPC1HPGDRAB9ASMN1; SMN2MEN1
SCHEMBL1618359 0.90 SMPD1 (0.48) NPC1HPGDRAB9ASMN1; SMN2SMPD1
SCHEMBL1616923 0.89 SMPD1 (0.46) NPC1HPGDRAB9ASMN1; SMN2MEN1
SCHEMBL1616920 0.89 SMPD1 (0.44) NPC1HPGDRAB9ASMN1; SMN2MEN1
SCHEMBL1618535 0.88 SMPD1 (0.45) NPC1HPGDRAB9ASMN1; SMN2MEN1
SCHEMBL1617930 0.88 ATM (0.47) NPC1HPGDRAB9ASMN1; SMN2SMPD1
SCHEMBL1616506 0.87 NPC1 (0.46) NPC1HPGDRAB9ASMN1; SMN2SMPD1
SCHEMBL8037100 0.86 SMPD1 (0.44) NPC1HPGDRAB9ASMN1; SMN2KMT2A
SCHEMBL12717270 0.86 SMPD1 (0.44) NPC1HPGDRAB9ASMN1; SMN2SMPD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2246338-B1 NOVEL CATECHOL DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, USE OF THE CATECHOL DERIVATIVE, AND USE OF THE PHARMACEUTICAL COMPOSITION KISSEI PHARMACEUTICAL (JP) 2013-11-20 EP disclosed
US-7923462-B2 Catechol derivative, pharmaceutical composition containing the same, use of the catechol derivative, and use of the pharmaceutical composition KISSEI PHARMACEUTICAL CO., LTD. (JP) 2011-04-12 US disclosed
US-20100280083-A1 NOVEL CATECHOL DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, USE OF THE CATECHOL DERIVATIVE, AND USE OF THE PHARMACEUTICAL COMPOSITION KISSEI PHARMACEUTICAL CO., LTD. (JP) 2010-11-04 US disclosed
EP-2246338-A1 NOVEL CATECHOL DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, USE OF THE CATECHOL DERIVATIVE, AND USE OF THE PHARMACEUTICAL COMPOSITION Kissei Pharmaceutical Co., Ltd. (JP) 2010-11-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100280083-A1 NOVEL CATECHOL DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, USE OF THE CATECHOL DERIVATIVE, AND USE OF THE PHARMACEUTICAL COMPOSITION COMT, CYP2D6, CYP3A43 HTT 629/4885NPC1 1524/4885HPGD 964/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.